Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.82 |
| ▸ | CA1 | P00915 | 6/20 | 0.82 |
| ▸ | PPARA | Q07869 | 4/20 | 0.78 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | RELA | Q04206 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108251 | 1.00 | CA2 (0.82) | CA2CA1PPARAEPHX1CA12 | |
| SCHEMBL80252 | 1.00 | CA2 (0.82) | CA2CA1PPARAEPHX1CA12 | |
| SCHEMBL1668208 | 1.00 | CA2 (0.82) | CA2CA1PPARAEPHX1CA12 | |
| SCHEMBL3787723 | 1.00 | CA2 (0.82) | CA2CA1PPARAEPHX1CA12 | |
| SCHEMBL3794668 | 1.00 | CA2 (0.82) | CA2CA1PPARAEPHX1CA12 | |
| SCHEMBL291897 | 1.00 | CA2 (0.82) | CA2CA1PPARAEPHX1CA12 | |
| SCHEMBL4622863 | 1.00 | CA2 (0.82) | CA2CA1PPARAEPHX1CA12 | |
| SCHEMBL3792229 | 1.00 | CA2 (0.82) | CA2CA1PPARAEPHX1CA12 | |
| SCHEMBL3124345 | 1.00 | CA2 (0.82) | CA2CA1PPARAEPHX1CA12 | |
| Fluoride SCHEMBL28507310 | 0.98 | CA2 (0.78) | CA2CA1PPARAEPHX1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| EP-1984326-B1 | ACYCLIC SULFAMIDE DERIVATIVES | FUND IMABIS INST MEDITTERANEO PARA EL AVAN E DE LA BIOTECNOLOGIA Y LA INVESTIG SANITARIA (ES) | 2017-05-03 | — | — | EP | claimed |
| US-9173953-B2 | Prodrugs containing an aromatic amine connected by an amido bond to a linker | ASCENDIS PHARMA AS (DK) | 2015-11-03 | — | — | US | claimed |
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | claimed |
| EP-2459227-A1 | PRODRUGS CONTAINING AN AROMATIC AMINE CONNECTED BY AN AMIDO BOND TO A LINKER | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | claimed |
| US-8188312-B2 | Acyclic sulfamide derivatives | FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) | 2012-05-29 | — | — | US | claimed |
| WO-2011012722-A1 | PRODRUGS CONTAINING AN AROMATIC AMINE CONNECTED BY AN AMIDO BOND TO A LINKER | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | claimed |
| US-20100179224-A2 | Acyclic Sulfamide Derivatives | FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) | 2010-07-15 | — | — | US | claimed |
| US-20100048712-A2 | Acyclic Sulfamide Derivatives | FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) | 2010-02-25 | — | — | US | claimed |
| US-20090221710-A1 | Acyclic Sulfamide Derivatives | FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) | 2009-09-03 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1984326-A1 | ACYCLIC SULFAMIDE DERIVATIVES | Fundacion Imabis. Inst. Meditteraneo para el Avan e de la Biotecnologia y la Investigacion Sanitaria (ES) | 2008-10-29 | — | — | EP | claimed |
| WO-2007085469-A1 | ACYCLIC SULFAMIDE DERIVATIVES | FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) | 2007-08-02 | — | — | WO | claimed |
| WO-2025129358-A1 | STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES | INTELGENX CORP. (CA) | 2025-06-26 | — | — | WO | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-5126234-A | Pyrazolone-based magenta coupler; low fog, high color density | FUJI PHOTO FILM CO., LTD. (JP) | 1992-06-30 | — | — | US | disclosed |
| US-4078930-A | ELECTROSTATOGRAPHIC | XEROX CORPORATION (US) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | DAO, DNPEP, DDC | CA2 857/4885CA1 1173/4885PPARA 2083/4885 |
| US-20100179224-A2 | Acyclic Sulfamide Derivatives | SULT2A1, STS, SUCNR1 | CA2 1092/4885CA1 1840/4885PPARA 346/4885 |
| US-20090221710-A1 | Acyclic Sulfamide Derivatives | STS, LIPE, FABP4 | CA2 2198/4885CA1 3726/4885PPARA 30/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | CA2 3860/4885CA1 2620/4885PPARA 4186/4885 |
| US-20100048712-A2 | Acyclic Sulfamide Derivatives | SULT2A1, STS, SUCNR1 | CA2 1092/4885CA1 1840/4885PPARA 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.